KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $85.9 million.

  • Emergent BioSolutions' Cost of Revenue fell 2993.47% to $85.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 14487.8%. This contributed to the annual value of $276.0 million for FY2024, which is 968.59% down from last year.
  • Per Emergent BioSolutions' latest filing, its Cost of Revenue stood at $85.9 million for Q3 2025, which was down 2993.47% from $66.9 million recorded in Q2 2025.
  • Emergent BioSolutions' Cost of Revenue's 5-year high stood at $440.5 million during Q4 2021, with a 5-year trough of -$287.3 million in Q4 2024.
  • In the last 5 years, Emergent BioSolutions' Cost of Revenue had a median value of $92.2 million in 2022 and averaged $77.8 million.
  • In the last 5 years, Emergent BioSolutions' Cost of Revenue plummeted by 14633.37% in 2022 and then surged by 10672.45% in 2023.
  • Over the past 5 years, Emergent BioSolutions' Cost of Revenue (Quarter) stood at $440.5 million in 2021, then crashed by 146.33% to -$204.1 million in 2022, then fell by 5.19% to -$214.7 million in 2023, then tumbled by 33.81% to -$287.3 million in 2024, then surged by 129.9% to $85.9 million in 2025.
  • Its Cost of Revenue was $85.9 million in Q3 2025, compared to $66.9 million in Q2 2025 and $88.5 million in Q1 2025.